To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
['Ciccone|Marco Matteo|MM|', 'Zito|Annapaola|A|', 'Devito|Fiorella|F|', 'Maiello|Maria|M|', 'Palmiero|Pasquale|P|']
D000284:Administration, Oral D000818:Animals D000925:Anticoagulants D001281:Atrial Fibrillation D065427:Factor Xa Inhibitors D006470:Hemorrhage D006801:Humans D020300:Intracranial Hemorrhages D011720:Pyrazoles D011728:Pyridones D054556:Venous Thromboembolism
Apixaban anticoagulant thrombosis. extracranial intracranial bleeding artial fibrillation